OUR TEAM

AT THIRD ROCK, PEOPLE ARE OUR MOST VALUABLE ASSET

We are a bi-coastal, multi-disciplinary team that brings together the best of science, strategy, business and medicine. Our team has a proven record of translating disruptive technologies into valuable business enterprises. We adhere to a “Third Rock Forever” philosophy, realizing that we have been phenomenally successful because of the contributions of the whole Third Rock team. Working closely with leading scientific and business visionaries, as well as industry partners, we identify opportunities to change the future of medicine and rigorously vet those ideas through our discovery process to develop the vision, strategy and plan needed to succeed.

MIKE BONNEY
PARTNER

Mike Bonney has more than 30 years of operational, commercial and senior management expertise in the biopharmaceutical industry. He was the CEO of Cubist for more than 10 years and held roles of increasing responsibility at Biogen and Zeneca Pharmaceuticals. Mike was a member of PhRMA until 2014 and was instrumental in getting Generating Antibiotic Incentives Now (GAIN) provisions signed into law in 2013, extending the term of exclusivity granted by FDA to innovative antibiotics.

ALEXIS BORISY
PARTNER

Alexis Borisy is an integral member of the Third Rock team and a successful company builder with more than 20 years of experience launching and operating innovative science-based organizations. Alexis focuses on the formation, development and strategy of new companies. Prior to joining Third Rock Ventures, Alexis founded CombinatoRx in 2000, serving as its CEO and bringing the company public on the NASDAQ just five years later.

DINA CIARIMBOLI
GENERAL COUNSEL

Dina Ciarimboli is responsible for advising on corporate strategic and tactical legal initiatives and providing management with advice on company strategies and implementation. Prior to joining Third Rock Ventures, Dina served as venture capital general counsel to several firms and before that, held a nearly 10-year tenure as general counsel for Prism VentureWorks, a venture firm focused on equity investments in start-up, early-stage and growth companies in the communications, internet and healthcare industries. Earlier, she served as an associate at Testa, Hurwitz & Thibeault, LLP and as a senior associate at PricewaterhouseCoopers.

CYNTHIA CLAYTON
HEAD OF COMMUNICATIONS

Cynthia Clayton focuses on identifying and initiating communication activities and best practices across the firm and in the portfolio. Prior to joining Third Rock Ventures, Cynthia served as the vice president, investor relations and corporate communications for Alnylam Pharmaceuticals for 10 years. Earlier, she was the director, investor relations and corporate communications at Synta Pharmaceuticals and Millennium Pharmaceuticals.

ALISON CONNORS
CONTROLLER

Alison Connors focuses on financial operations, reporting and analysis for the fund and assisting new portfolio companies with their initial financial operations. Alison has more than 10 years of financial accounting experience within the biotechnology and life science industries. Prior to joining Third Rock Ventures, she held various senior financial roles at Prism VentureWorks and Bain Capital. She also worked at PricewaterhouseCoopers, providing management and consultant services to biotechnology companies.

ALEXANDRA DICKSON
SENIOR ASSOCIATE

Alexandra Dickson focuses on new company formation and due diligence. Prior to joining Third Rock Ventures, Alexandra was a Blavatnik Fellow at Harvard University, where she worked to commercialize a novel technology for in vitro fertilization. Prior to her fellowship, Alexandra was a manager of business analytics at Biogen, supporting the hemophilia franchise.

ANDREA DIMELLA
SENIOR RECRUITING MANAGER

Andrea DiMella focuses on cross-functional recruiting to build teams within Third Rock Ventures’ portfolio companies, as well as performing executive searches for the firm. She has nearly 20 years of experience across the biotechnology and pharmaceutical industries, utilizing creative talent strategies to address organizational and client talent acquisition needs. Prior to joining Third Rock Ventures, Andrea worked in roles of increasing importance at Biogen Idec, serving most recently as principal partner, global executive search. Before Biogen, she served as senior manager of staffing at Genentech, and staffing consultant at Amgen before that.

MICHIELLE DOIG
DIRECTOR OF CORPORATE FINANCE

Michelle Doig has nearly 20 years of experience advising life sciences companies on private placements, public equity financing and M&A transactions. Michelle has executed more than 20 equity and convertible transactions and numerous IPOs, private placements and M&A transactions for companies including Gilead, Dicerna, MedImmune, Millennium, Illumina and Seprocor.
APRIL EFFORT EUGENE
ASSOCIATE
April Effort Eugene works primarily with the partner development team to build relationships with industry partners and support business development efforts for discovery and portfolio companies. Prior to joining Third Rock Ventures, she served as director of business development, life sciences at the Boston University Technology Development Office and worked for the Coulter Foundation’s Translational Research Program at the University of Michigan.

NEIL EXTER
PARTNER
Neil Exter has more than 20 years of business development and strategic experience facilitating the successful development and implementation of operations and collaborations across the spectrum of newly emerging and established biotech companies, including Alantos Pharmaceuticals and Millennium Pharmaceuticals.

RICHARD GASTER, M.D., PH.D.
SENIOR ASSOCIATE
Rich Gaster focuses on new company formation and due diligence. Prior to joining Third Rock Ventures, Rich served as a resident physician in Harvard’s Plastic and Reconstructive Surgery Program. During his residency he worked at Massachusetts General Hospital, Brigham and Women’s Hospital and Beth Israel Deaconess Medical Center. He also has experience starting his own companies, founding Gaster Hall Technologies and wearBiō.

FRANK GENTILE, PH.D.
ENTREPRENEUR-IN-RESIDENCE
Frank Gentile brings nearly 25 years of experience working with pharmaceutical and biotechnology companies and currently serves as an adjunct professor of pharmacology and biotechnology in the division of biology and medicine at Brown University. He spent 12 years with Tekla Capital Management LLC, formerly Hambrecht & Quist Capital Management LLC, where he most recently served as senior vice president. Prior to Tekla, Frank oversaw technology research and development programs while serving as vice president, technology program management at Millennium Pharmaceuticals and earlier in his role as vice president, product development at Curis.

JAMES GERAGHTY
ENTREPRENEUR-IN-RESIDENCE
Jim Geraghty assists in the creation of companies focused on rare genetic diseases and supports existing portfolio companies in related spaces. He is a 20-year veteran of Genzyme Corporation, where he helped launch rare disease therapies around the world. Prior to joining Third Rock Ventures, Jim served as senior vice president, North America strategy and business development at Sanofi.

KEVIN GILLIS
PARTNER, CHIEF FINANCIAL OFFICER
Kevin Gillis has more than 20 years of financial experience, successfully designing and managing the financial operations for emerging and established biotech companies. Prior to joining Third Rock Ventures, he was vice president of finance at Coley Pharmaceutical Group and served in a number of senior finance roles at Millennium Pharmaceuticals and The Coca-Cola Company.

MARK GOLDSMITH, M.D., PH.D.
VENTURE PARTNER
Mark Goldsmith participates in the ideation, development and leadership of new companies. Prior to joining the firm, Mark was president and CEO of Constellation Pharmaceuticals, a leading biopharmaceutical company in the field of epigenetics and a Third Rock Ventures portfolio company. Before Constellation, Mark held senior executive positions in the biotechnology industry and academia.

JEAN-CHRISTOPHE HARMANGE, PH.D.
ENTREPRENEUR-IN-RESIDENCE
Jean-Christophe focuses on drug discover and development. Prior to joining Third Rock Ventures, Jean-Christophe was the executive director of drug discovery at Constellation Pharmaceuticals. Previously, he occupied positions of increasing responsibilities at Amgen, Eisai and Servier. Additionally, he is co-inventor on more than 30 issued U.S. patents and the author of numerous publications.

CHARLES HOMCY, M.D.
VENTURE PARTNER
Charles Homcy focuses on the formation of companies discovering and developing novel therapeutic approaches, and is responsible for leading Third Rock Ventures’ West Coast office. Prior to joining Third Rock Ventures, Charles co-founded Portola Pharmaceuticals and served as president and CEO. Prior to that, he was president of R&D at Millennium following its acquisition of COR Therapeutics in 2002.

CHRISTINA ISACSON, PH.D.
PRINCIPAL
Christina Isacson helps lead the partner development team, working to build and maintain strong relationships with larger industry partners. Prior to joining Third Rock Ventures, Christina was senior director, business development at Ironwood Pharmaceuticals, where she played a major role in establishing and managing the in-licensing efforts as a new initiative for the company.

CHELSEA PLACE JOHNSON, PH.D.
ASSOCIATE
Chelsea Place Johnson focuses on new company formation and due diligence in the area of oncology. Prior to joining Third Rock Ventures, she was a graduate student researcher at the Dana-Farber Cancer Institute and Broad Institute while obtaining her Ph.D. in biological chemistry and molecular pharmacology from Harvard University. While there, she received the Ruth L. Kirschstein National Research Service Award for Individual Predoctoral Fellows.

ROBERT KAMEN, PH.D.
ENTREPRENEUR-IN-RESIDENCE
Bob Kamen brings more than 30 years of experience in the pharmaceutical and biotechnology industries, serving most recently as president of Abbott Bioresearch Center, where he oversaw the discovery and production of Humira®, the first fully human antibody to achieve marketing approval in the U.S. and Europe, and was a member of the Abbott Pharmaceuticals Executive Management Committee.

APRIL EFFORT EUGENE
ASSOCIATE
April Effort Eugene works primarily with the partner development team to build relationships with industry partners and support business development efforts for discovery and portfolio companies. Prior to joining Third Rock Ventures, she served as director of business development, life sciences at the Boston University Technology Development Office and worked for the Coulter Foundation’s Translational Research Program at the University of Michigan.

NEIL EXTER
PARTNER
Neil Exter has more than 20 years of business development and strategic experience facilitating the successful development and implementation of operations and collaborations across the spectrum of newly emerging and established biotech companies, including Alantos Pharmaceuticals and Millennium Pharmaceuticals.

RICHARD GASTER, M.D., PH.D.
SENIOR ASSOCIATE
Rich Gaster focuses on new company formation and due diligence. Prior to joining Third Rock Ventures, Rich served as a resident physician in Harvard’s Plastic and Reconstructive Surgery Program. During his residency he worked at Massachusetts General Hospital, Brigham and Women’s Hospital and Beth Israel Deaconess Medical Center. He also has experience starting his own companies, founding Gaster Hall Technologies and wearBiō.

FRANK GENTILE, PH.D.
ENTREPRENEUR-IN-RESIDENCE
Frank Gentile brings nearly 25 years of experience working with pharmaceutical and biotechnology companies and currently serves as an adjunct professor of pharmacology and biotechnology in the division of biology and medicine at Brown University. He spent 12 years with Tekla Capital Management LLC, formerly Hambrecht & Quist Capital Management LLC, where he most recently served as senior vice president. Prior to Tekla, Frank oversaw technology research and development programs while serving as vice president, technology program management at Millennium Pharmaceuticals and earlier in his role as vice president, product development at Curis.

JAMES GERAGHTY
ENTREPRENEUR-IN-RESIDENCE
Jim Geraghty assists in the creation of companies focused on rare genetic diseases and supports existing portfolio companies in related spaces. He is a 20-year veteran of Genzyme Corporation, where he helped launch rare disease therapies around the world. Prior to joining Third Rock Ventures, Jim served as senior vice president, North America strategy and business development at Sanofi.

KEVIN GILLIS
PARTNER, CHIEF FINANCIAL OFFICER
Kevin Gillis has more than 20 years of financial experience, successfully designing and managing the financial operations for emerging and established biotech companies. Prior to joining Third Rock Ventures, he was vice president of finance at Coley Pharmaceutical Group and served in a number of senior finance roles at Millennium Pharmaceuticals and The Coca-Cola Company.

MARK GOLDSMITH, M.D., PH.D.
VENTURE PARTNER
Mark Goldsmith participates in the ideation, development and leadership of new companies. Prior to joining the firm, Mark was president and CEO of Constellation Pharmaceuticals, a leading biopharmaceutical company in the field of epigenetics and a Third Rock Ventures portfolio company. Before Constellation, Mark held senior executive positions in the biotechnology industry and academia.

JEAN-CHRISTOPHE HARMANGE, PH.D.
ENTREPRENEUR-IN-RESIDENCE
Jean-Christophe focuses on drug discover and development. Prior to joining Third Rock Ventures, Jean-Christophe was the executive director of drug discovery at Constellation Pharmaceuticals. Previously, he occupied positions of increasing responsibilities at Amgen, Eisai and Servier. Additionally, he is co-inventor on more than 30 issued U.S. patents and the author of numerous publications.

CHARLES HOMCY, M.D.
VENTURE PARTNER
Charles Homcy focuses on the formation of companies discovering and developing novel therapeutic approaches, and is responsible for leading Third Rock Ventures’ West Coast office. Prior to joining Third Rock Ventures, Charles co-founded Portola Pharmaceuticals and served as president and CEO. Prior to that, he was president of R&D at Millennium following its acquisition of COR Therapeutics in 2002.

CHRISTINA ISACSON, PH.D.
PRINCIPAL
Christina Isacson helps lead the partner development team, working to build and maintain strong relationships with larger industry partners. Prior to joining Third Rock Ventures, Christina was senior director, business development at Ironwood Pharmaceuticals, where she played a major role in establishing and managing the in-licensing efforts as a new initiative for the company.

CHELSEA PLACE JOHNSON, PH.D.
ASSOCIATE
Chelsea Place Johnson focuses on new company formation and due diligence in the area of oncology. Prior to joining Third Rock Ventures, she was a graduate student researcher at the Dana-Farber Cancer Institute and Broad Institute while obtaining her Ph.D. in biological chemistry and molecular pharmacology from Harvard University. While there, she received the Ruth L. Kirschstein National Research Service Award for Individual Predoctoral Fellows.

ROBERT KAMEN, PH.D.
ENTREPRENEUR-IN-RESIDENCE
Bob Kamen brings more than 30 years of experience in the pharmaceutical and biotechnology industries, serving most recently as president of Abbott Bioresearch Center, where he oversaw the discovery and production of Humira®, the first fully human antibody to achieve marketing approval in the U.S. and Europe, and was a member of the Abbott Pharmaceuticals Executive Management Committee.
JOHN KEILTY  
GENERAL MANAGER, PLATFORM OPERATIONS

John Keilty works with the platform team to develop, implement and refine technology roadmaps for Third Rock Ventures portfolio companies with a focus on the identification and integration of drug discovery and development technology platforms. Prior to joining the firm, John was the vice president of information technology and informatics at Infinity Pharmaceuticals, where he played a critical role for nearly 13 years, and was an early member of Millennium Pharmaceuticals.

VIKTORIA KHEIFETS, PH.D.  
SENIOR ASSOCIATE

Viktoria Kheifets focuses on new company formation and due diligence. Prior to joining Third Rock Ventures, she was a senior group leader of Discovery Biology at Edison Pharmaceuticals where she headed drug discovery efforts in orphan mitochondrial diseases and diseases of aging. Prior to Edison, Viktoria was at Ampelion Life Sciences, where she led skin aging and medical foods research programs.

WALTER KOWTONIUK, PH.D.  
SENIOR ASSOCIATE

Walt Kowtoniuk focuses on new company formation and due diligence in the area of rare genetic diseases. Prior to joining Third Rock Ventures, Walt was a manager at Clarion Healthcare, where he focused on developing new business strategies and providing commercial insight into early product development in the rare disease space.

MARK LEVIN  
PARTNER

Mark Levin is a Third Rock Ventures co-founder and an industry leader with 40 years of experience building and operating leading biotech companies. Mark co-founded Mayfield Fund’s life sciences effort, where he was also the founding CEO of Tulark, Cell Genesys/ Abgenix, Focal, Stem Cells and Millennium Pharmaceuticals. Mark served as CEO of Millennium Pharmaceuticals for 12 years.

JAKOB LOVEN, PH.D.  
SENIOR ASSOCIATE

Jakob Loven focuses on new company formation and due diligence with particular emphasis on oncology and emerging technologies. Prior to joining Third Rock Ventures, Jakob was a founding scientist at Syros Pharmaceuticals, a postdoctoral fellow in the Young Lab at the Whitehead Institute for Biomedical Research and a research scientist at the Department of Biology Sciences, AstraZeneca R&D in Sweden.

DANIEL LYNCH  
VENTURE PARTNER

Dan Lynch brings more than 25 years of experience serving in management positions in the biotechnology and pharmaceutical industries. Until March 2012, he was executive chairman of the board for two companies – Avila Therapeutics, which was sold to Celgene, and Stromedix, Inc., which was sold to Biogen Idec. Dan spent nearly five years at ImClone Systems, serving as CEO and CFO.

THOMAS MARTZ  
SENIOR ASSOCIATE

Thomas Martz focuses on new company formation and due diligence, with an emphasis on oncology. Prior to joining Third Rock Ventures, Thomas obtained his MBA from the MIT Sloan School of Management, where he interned in multiple strategic and business development roles at biotechnology companies including Abgenix Pharmaceuticals, Editas Medicine and Eleven Biotherapeutics. Previously, Thomas was a senior consultant in Deloitte's Life Sciences practice.

GREG MCGRAW  
ACCOUNTING MANAGER

Greg McGraw focuses on financial operations of the management company, fund reporting and analysis, as well as assisting portfolio companies with accounting needs. Prior to joining Third Rock Ventures, Greg was a tax manager at Deloitte Tax, LLP, where he provided tax compliance and consulting to various hedge, private equity and venture capital clients.

CRAIG MUIR  
PARTNER AND CHIEF TECHNOLOGY OFFICER

Craig Muir has more than 25 years of technology development, implementation and application experience across the biotechnology and pharmaceutical industries. Prior to joining Third Rock Ventures, Craig served as senior vice president, technical operations for Codon Diagnostics and also spent 12 years at Millennium Pharmaceuticals as vice president of platform technology. Earlier in his career, Craig served in a number of technology development and scientific roles at Genentech, Tularik and the University of Vermont.

TRACY NICHOLSON  
SENIOR RECRUITING MANAGER

Tracy Nicholson focuses on cross-functional recruiting searches to build teams within the portfolio companies, as well as recruiting for the firm. She has 15 years of pharmaceutical and biotechnology-focused recruiting experience, and prior to joining Third Rock Ventures, was the human resources manager at Agios Pharmaceuticals and consulted at larger biotech and pharmaceutical companies.

STEVEN PAUL, M.D.  
VENTURE PARTNER

Steve Paul, with more than 35 years of scientific experience, serves as a senior advisor to the firm and participates in the ideation and development of potential new companies. Steve has had a distinguished career in neuroscience, particularly in CNS drug discovery and development. He is the former president of the Lilly Research Laboratories of Eli Lilly and Company and now leads the Helen & Robert Appel Institute for Alzheimer's Research at Weill Cornell Medical College.

CARY PFEFFER, M.D.  
PARTNER

Cary Pfeffer has more than 20 years of business development and transaction experience, facilitating the successful development and implementation of leading collaborations across the spectrum of newly emerging and established biotech companies. Prior to Third Rock Ventures, Cary founded The Pfeffer Group and spent 10 years at Biogen in a variety of executive domestic and international management roles focused on business and market development, product development and commercial operations.

PHILIP REILLY, M.D., J.D.  
VENTURE PARTNER

Phil Reilly supports the firm's advancement of new ventures, with a focus on growing transformational companies dedicated to breakthrough treatments for genetic disorders. Phil served as the former CEO and chairman of the board of Interleukin Genetics, Inc., and is currently a trustee of Cornell University. He served as president of the American Society of Law, Medicine, and Ethics, and is a founding fellow of the American College of Medical Genetics.
CHRIS ROBINSON  
RECRUITING DIRECTOR

Chris Robinson focuses on executive-level searches for the portfolio companies, as well as recruiting for the firm. He has more than 15 years of research and development-focused recruiting experience in life sciences and high technology. Prior to joining Third Rock Ventures, Chris was the co-founder of Pivotal Search, a boutique life sciences executive search and recruiting consulting practice, and was also one of the founding members of a life sciences R&D practice at another national search firm.

JESSICA SCHOENIG  
STAFF ACCOUNTANT

Jessica Schoenig focuses on financial operations of the management company and assists portfolio companies with accounting needs. Prior to joining Third Rock Ventures, Jessica was a senior tax consultant at Deloitte Tax, LLP, where she held multiple roles of increasing responsibility and focuses on serving hedge fund and private equity clients on a variety of tax compliance needs.

STEPHEN SHERWIN, M.D.  
ENTREPRENEUR-IN-RESIDENCE

Steve Sherwin brings more than 30 years of experience in the pharmaceutical and biotechnology industries, and focuses on discovery stage products. Prior to joining Third Rock Ventures, Steve was the CEO of Cell Genesys from 1990 until 2009. He was also a co-founder and chairman of Abgenix, and more recently, Steve was the chairman of BIO and is currently a board member of several leading biotechnology companies.

KEVIN STARR  
PARTNER

Kevin Starr is a Third Rock Ventures co-founder and a proven operational leader with more than 25 years of experience building and operating leading biotech companies. Prior to Third Rock Ventures, Kevin was COO and CFO at Millennium Pharmaceuticals. Earlier in his career, he served in various executive roles at Biogen and Digital Equipment Corporation. He currently serves on the board of directors for several leading biotech companies.

ROBERT TEPPER, M.D.  
PARTNER

Bob Tepper is a Third Rock Ventures co-founder and a distinguished scientist with more than 30 years of experience building and operating leading R&D operations. Prior to joining Third Rock Ventures, Bob was president of R&D at Millennium Pharmaceuticals and was vital in its expansion from a drug discovery company to a fully integrated biopharmaceutical company. Prior to Millennium, Bob co-founded Cell Genesys/Abgenix. Bob serves as an adjunct faculty member at Harvard Medical School and Massachusetts General Hospital and is an advisory board member of several leading health care institutions.

STEFAN VITOROVIC  
SENIOR ASSOCIATE

Stefan Vitorovic focuses on new company formation and due diligence. He is also closely involved with portfolio company financings, as well as expanding relationships with potential partners and advisers. Prior to joining Third Rock Ventures, Stefan served as an associate for TPG Capital’s North America Buyouts Group and as an analyst for healthcare investment banking at Credit Suisse.

BARBARA WEBER, M.D.  
ENTREPRENEUR-IN-RESIDENCE

Barbara Weber brings over 25 years of experience working in oncology research and spent the last six years at Novartis, where she held the position of senior vice president and global head of oncology translational medicine. Prior to joining Novartis, Barbara served as vice president of three groups at GlaxoSmithKline, including Global Biomarkers, Oncology Discovery and Translational Medicine, and Cancer Metabolism Drug Discovery. Until 2005, Barbara was a professor of medicine and genetics at The University of Pennsylvania School of Medicine, heading a clinical and translational research program in cancer genetics and the UPenn Cancer Center Breast Cancer program.